Neuronata-R Retains Conditional Approval in South Korea as CorestemChemon Eyes U.S. Expansion
核心洞察
South Korea's MFDS updated Neuronata-R's conditional approval in May 2026, keeping the stem cell therapy available for ALS patients based on completed Phase 3 data.
In the ALSUMMIT trial, Neuronata-R missed statistical significance in the full population but met primary and secondary endpoints in the slow-progressor subgroup.
CorestemChemon (搜索) is pursuing a Type C meeting with the FDA and aims to file a Biologics License Application for U.S. approval next year.
South Korea's Ministry of Food and Drug Safety (MFDS) has updated the conditional approval of Neuronata-R (lenzumestrocel), an autologous stem cell therapy for amyotrophic lateral sclerosis (搜索) (ALS), allowing the product to remain on the market. The decision, finalized in May 2026, updates the therapy's label to incorporate data from the completed ALSUMMIT Phase 3 clinical trial (NCT04745299). Neuronata-R was first granted conditional approval in South Korea in 2014, and the latest regulatory action ensures continued patient access while developer CorestemChemon (搜索) works to resume manufacturing and build a U.S. research presence.
ALSUMMIT Trial Results and the Slow-Progressor Subgroup
In the ALSUMMIT Phase 3 trial, Neuronata-R did not achieve statistical significance across the full study population. However, in a prespecified subgroup of slow progressors, the therapy met its primary endpoint — the Combined Assessment of Function and Survival (CAFS) — as well as a key secondary endpoint, the ALS Functional Rating Scale-Revised (ALSFRS-R). The subgroup also demonstrated consistent improvement in slow vital capacity (SVC).
Notably, treatment in the slow-progressor subgroup was associated with reduced levels of neurofilament light chain (搜索) (NfL), a biomarker of axonal damage released when neurons are injured. NfL is gaining acceptance as a key biomarker in ALS and is increasingly recognized as a basis for regulatory decisions on disease-modifying therapies.
Mechanism of Action and Clinical Experience
Neuronata-R uses autologous bone marrow-derived mesenchymal stem cells (MSCs), expanded in the laboratory from the patient's own bone marrow and administered via intrathecal injection. Rather than replacing motor neurons directly, the MSCs are believed to act through secreted factors. These include anti-inflammatory mediators — TGF-β1 (搜索), IL-4 (搜索), and IL-10 — that help dampen the neuroinflammation contributing to motor neuron loss, as well as neuroprotective factors such as VEGF (搜索), BDNF, and IGF (搜索), which support neuronal survival. Together, these factors are proposed to slow motor neuron death.
To date, the therapy has been administered to more than 400 patients in South Korea, generating a substantial body of real-world experience and safety data. Neuronata-R holds Orphan Drug Designation from the U.S. Food and Drug Administration (搜索) (FDA), granted in 2018, and from the European Medicines Agency (搜索) (EMA), granted in 2019.
U.S. Expansion and Regulatory Pathway
CorestemChemon (搜索) has been actively establishing a presence in the United States. In late 2025, the company became the first South Korean firm to join an innovation engine supported by the U.S. National Science Foundation (NSF) — the Piedmont Triad Regenerative Medicine Engine, anchored by the Wake Forest Institute for Regenerative Medicine (搜索) (WFIRM). This membership provides access to WFIRM's research infrastructure and network, and CorestemChemon has consolidated its U.S. operations in North Carolina to anchor that work.
On the regulatory front, CorestemChemon (搜索) is pursuing a Type C meeting with the FDA, with the goal of filing a Biologics License Application (BLA) for U.S. approval next year. Full-scale production of Neuronata-R is expected to be operational by early next year, at which point treatment will resume. Once manufacturing restarts, patients from outside South Korea will also be able to travel to the country to receive the therapy.
CorestemChemon (搜索) has characterized the MFDS decision as a step toward maintaining a cell-based treatment option for the patients most likely to benefit, while laying the groundwork to extend that option to patients beyond South Korea over time.